Brain zapping study aims to unlock Cerebellum's secrets for better therapies
NCT ID NCT07561229
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a non-invasive brain stimulation technique called rTMS affects two different areas of the cerebellum in 40 healthy adults. One area is linked to movement, the other to thinking and attention. By comparing the effects, researchers hope to learn which brain regions to target for future treatments of conditions like stroke and schizophrenia. There is no direct benefit to participants, but the findings could help develop better therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subject, male or female, aged between 18 and 60 years inclusive * Subject affiliated with or a beneficiary of a social security health insurance scheme * Subject has dated and signed the informed consent form prior to the start of any trial-related procedures * For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study Exclusion Criteria: * Subject with substance use disorders (as defined by the DSM-5) * Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product) * Subject suffering from a neurological pathology or sequelae * Subject with Attention-Deficit/Hyperactivity Disorder (ADHD) * Subject with Borderline Personality Disorder * Subject presenting with disabling sensory impairments, specifically a visual acuity (corrected, if applicable) \< 0.8 (due to the use of visual materials; Freiburg Vision Test, Bach 1996; verified during an examination at the screening visit) * Subject deprived of liberty or under legal protection * Subject under guardianship or trusteeship * Pregnant or breastfeeding woman (verified by a urinary test at the screening visit) * Subject within an exclusion period defined by another clinical study or participating in a study likely to impact the results of the research * Subject presenting a contraindication for fMRI or rTMS: presence of non-removable ferromagnetic bodies, prostheses, pacemakers, implanted medication pumps, vascular clips or stents, heart valves or ventricular shunts, certain intracerebral clips, cochlear implants, history of seizures (epilepsy), or skin breach/pathology at the point of contact with the electrodes * Subject with a history of major neurological or psychiatric disease with current psychotropic medication (i.e., antipsychotics, benzodiazepines and related compounds, or hypnotics)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can magnetic brain zaps ease the pain of a sleepless body?
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Can poor sleep make you hurt more? study probes Insomnia's link to pain
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Does soreness after exercise disrupt sleep more for people with insomnia?